M
Martin S. Weber
Researcher at University of Göttingen
Publications - 72
Citations - 2191
Martin S. Weber is an academic researcher from University of Göttingen. The author has contributed to research in topics: Multiple sclerosis & Experimental autoimmune encephalomyelitis. The author has an hindex of 22, co-authored 72 publications receiving 1373 citations. Previous affiliations of Martin S. Weber include University of California & Boehringer Ingelheim.
Papers
More filters
Journal ArticleDOI
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban,Douglas L. Arnold,Martin S. Weber,Ivan Staikov,Karolina Piasecka-Stryczynska,Jonathan Willmer,Emily Martin,Fernando Dangond,Sana Syed,Jerry S. Wolinsky +9 more
TL;DR: Patients with relapsing multiple sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions during weeks 12 through 24 than those who received placebo and there was no significant effect of trial group on the change from baseline in the EDSS score.
Journal ArticleDOI
Defining distinct features of anti-MOG antibody associated central nervous system demyelination.
TL;DR: It is proposed that MOG+ CNS demyelinating disease represents a distinct novel disease entity and mechanistic insight is provided on how this peripheral anti-MOG ab response may be of pathogenetic relevance in triggering acute flares of inflammatory CNS Demyelination.
Journal ArticleDOI
Immunological Aspects of Approved MS Therapeutics.
Paulus S. Rommer,Ron Milo,May H. Han,Sammita Satyanarayan,Johann Sellner,Larissa Hauer,Zsolt Illes,Clemens Warnke,Sarah Laurent,Martin S. Weber,Yinan Zhang,Olaf Stüve +11 more
TL;DR: The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS and each agent's clinical development and potential side effects are discussed.
Journal ArticleDOI
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.
TL;DR: An outlook is provided on how this currently differentiating concept of pro- and anti-inflammatory B- cell function could be harnessed to further improve safety and effectiveness of B-cell-directed therapeutic approaches in MS.
Journal ArticleDOI
Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients
Sven Jarius,Hannah L. Pellkofer,Nadja Siebert,Mirjam Korporal-Kuhnke,Martin W. Hümmert,Marius Ringelstein,Paulus S. Rommer,Ilya Ayzenberg,Klemens Ruprecht,Luisa Klotz,Nasrin Asgari,Tobias Zrzavy,Romana Höftberger,Rafik Tobia,Mathias Buttmann,Kai Fechner,Kathrin Schanda,Martin S. Weber,Susanna Asseyer,Jürgen Haas,Christian Lechner,Ingo Kleiter,Orhan Aktas,Corinna Trebst,Kevin Rostasy,Markus Reindl,Tania Kümpfel,Friedemann Paul,Brigitte Wildemann +28 more
TL;DR: MOG-IgG-positive EM is characterized by CSF features that are distinct from those in multiple sclerosis, important for the differential diagnosis of MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.